Philippe Robert

Philippe Robert

Auto-generated profile, based on publicly available information

Philippe Robert

From the Guerbet, Research and Innovation Department, Aulnay-sous-Bois, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Investigative Radiology
Verified
Journal Article
Open access
PRPhilippe Robert
Philippe Robert
SLStéphane Lehericy
Stéphane Lehericy
SGSylvie Grand
Sylvie Grand
XVXavier Bs Violas
Xavier Bs Violas
NFNathalie Fretellier
Nathalie Fretellier
CCClaire Corot
Claire Corot
Objectives To prospectively compare in healthy rats the effect of multiple injections of macrocyclic (gadoterate meglumine) and linear (gadodiamide) gadolinium-based contrast agents (GBCAs) on T1-weighted signal intensity in the deep cerebellar nuclei (DCN), including the dentate nucleus. Materials and Methods Healthy rats (n = 7/group) received 20 intravenous injections of 0.6 mmol of gadolinium (Gd) per kilogram (4 injections per week during 5 weeks) of gadodiamide, gadoterate meglumine, or hyperosmolar saline (control group). Brain T1-weighted magnetic resonance imaging was performed before and once a week during the 5 weeks of injections and during 5 additional weeks (treatment-free period). Gadolinium concentrations were measured with inductively coupled plasma mass spectrometry in plasma and brain. Blinded qualitative and quantitative evaluations of the T1 signal intensity in DCN were performed, as well as a statistical analysis on quantitative data. Results A significant and persistent T1 signal hyperintensity in DCN was observed only in gadodiamide-treated rats. The DCN-to-cerebellar cortex signal ratio was significantly increased from the 12th injection of gadodiamide (1.070 ± 0.024) compared to the gadoterate meglumine group (1.000 ± 0.033; P < 0.001) and control group (1.019 ± 0.022; P < 0.001) and did not significantly decrease during the treatment-free period. Total Gd concentrations in the gadodiamide group were significantly higher in the cerebellum (3.66 ± 0.91 nmol/g) compared with the gadoterate meglumine (0.26 ± 0.12 nmol/g; P < 0.05) and control (0.06 ± 0.10 nmol/g; P < 0.05) groups. Conclusions Repeated administrations of the linear GBCA gadodiamide to healthy rats are associated with progressive and persistent T1 signal hyperintensity in the DCN, with Gd deposition in the cerebellum in contrast with the macrocyclic GBCA gadoterate meglumine for which no effect was observed.

1 February 2016 in Investigative Radiology
Verified
Journal Article
Open access
PRPhilippe Robert
Philippe Robert
XVXavier Violas
Xavier Violas
SGSylvie Grand
Sylvie Grand
SLStéphane Lehericy
Stéphane Lehericy
JIJean-Marc Idée
Jean-Marc Idée
CCClaire Corot
Claire Corot
The aim of this study was to evaluate Gd retention in the deep cerebellar nuclei (DCN) of linear gadolinium-based contrast agents (GBCAs) compared with a macrocyclic contrast agent. The brain tissue retention of Gd of 3 linear GBCAs (gadobenate dimeglumine, gadopentetate dimeglumine, and gadodiamide) and a macrocyclic GBCA (gadoterate meglumine) was compared in healthy rats (n = 8 per group) that received 20 intravenous injections of 0.6 mmol Gd/kg (4 injections per week for 5 weeks). An additional control group with saline was included. T1-weighted magnetic resonance imaging was performed before injection and once a week during the 5 weeks of injections and for another 4 additional weeks after contrast period. Total gadolinium concentration was measured with inductively coupled plasma mass spectrometry. Blinded qualitative and quantitative evaluations of the T1 signal intensity in DCN were performed, as well as a statistical analysis on quantitative data. At completion of the injection period, all the linear contrast agents (gadobenate dimeglumine, gadopentetate dimeglumine, and gadodiamide) induced a significant increase in signal intensity in DCN, unlike the macrocyclic GBCA (gadoterate meglumine) or saline. The T1 hypersignal enhancement kinetic was fast for gadodiamide. Total Gd concentrations for the 3 linear GBCAs groups at week 10 were significantly higher in the cerebellum (1.21 ± 0.48, 1.67 ± 0.17, and 3.75 ± 0.18 nmol/g for gadobenate dimeglumine, gadopentetate dimeglumine, and gadodiamide, respectively) than with the gadoterate meglumine (0.27 ± 0.16 nmol/g, P < 0.05) and saline (0.09 ± 0.12 nmol/g, P < 0.05). No significant difference was observed between the macrocyclic agent and saline. Repeated administrations of the linear GBCAs gadodiamide, gadobenate dimeglumine, and gadopentetate dimeglumine to healthy rats were associated with progressive and significant T1 signal hyperintensity in the DCN, along with Gd deposition in the cerebellum. This is in contrast with the macrocyclic GBCA gadoterate meglumine for which no effect was observed.

1 August 2018 in Radiology
Verified
Journal Article
Open access
PRPhilippe Robert
Philippe Robert
SFStefanie Fingerhut
Stefanie Fingerhut
CFCécile Factor
Cécile Factor
VVVéronique Vives
Véronique Vives
JLJustine Letien
Justine Letien
UKUwe Karst
Uwe Karst
Unlike repeated administrations of gadoterate meglumine, repeated administrations of gadodiamide were associated with persistent signal hyperintensity in the deep cerebellar nuclei on T1-weighted sequences and long-term retention of chemically non-inert gadolinium, demonstrating that the level and chemical forms of gadolinium deposition depend on the structure of the gadolinium-based contrast agent. Purpose To compare the long-term brain elimination kinetics and gadolinium species in healthy rats after repeated injections of the contrast agents gadodiamide (a linear contrast agent) or gadoterate (a macrocyclic contrast agent). Materials and Methods Nine-week-old rats received five doses of 2.4 mmol gadolinium per kilogram of body weight over 5 weeks and were followed for 12 months with T1-weighted MRI (n = 140 rats, corresponding to seven time points, two contrast agents, and 10 rats per group). Animals were sacrificed at 1 week, 1 month, and 2, 3, 4, 5, and 12 months after the last injection. Brain and plasma were sampled to determine the total gadolinium concentration by using inductively coupled plasma mass spectrometry (ICP-MS). For the cerebellum, gadolinium speciation analysis was performed after mild extraction at four time points (1 month and 3, 5, and 12 months after the last injection) by using size exclusion chromatography and hydrophilic interaction liquid chromatography, both coupled to ...

1 January 2020 in Radiology
Verified
Journal Article
Open access
PRPhilippe Robert
Philippe Robert
VVVéronique Vives
Véronique Vives
AGAnne-Laure Grindel
Anne-Laure Grindel
SKStéphane Kremer
Stéphane Kremer
GBGuillaume Bierry
Guillaume Bierry
CCClaire Corot
Claire Corot
Gadopiclenol had approximately twofold higher T1 relaxivity at MRI compared with the gadolinium-based contrast agents gadoterate, gadobenate, and gadobutrol; 0.1 mmol/kg of gadopiclenol had approxi... Background Detection of cerebral lesions at MRI may benefit from a chemically stable and more sensitively detected gadolinium-based contrast agent (GBCA). Gadopiclenol, a macrocyclic GBCA with at l...

1 September 2018 in Investigative Radiology
Verified
Journal Article
Open access
PDF file
PRPhilippe Robert
Philippe Robert
TFThomas Frenzel
Thomas Frenzel
CFCécile Factor
Cécile Factor
GJGregor Jost
Gregor Jost
MRMarlène Rasschaert
Marlène Rasschaert
HPHubertus Pietsch
Hubertus Pietsch
Gadolinium (Gd)-based contrast agents (GBCAs) are pharmaceuticals that have been approved for 30 years and used daily in millions of patients worldwide. Their clinical benefits are indisputable. Recently, unexpected long-term presence of Gd in the brain has been reported by numerous retrospective clinical studies and confirmed in preclinical models particularly after linear GBCA (L-GBCA) compared with macrocyclic GBCA (M-GBCA). Even if no clinical consequences of Gd presence in brain tissue has been demonstrated so far, in-depth investigations on potential toxicological consequences and the fate of Gd in the body remain crucial to potentially adapt the clinical use of GBCAs, as done during the nephrogenic systemic fibrosis crisis. Preclinical models are instrumental in the understanding of the mechanism of action as well as the potential safety consequences. However, such models may be associated with risks of biases, often related to the protocol design. Selection of adequate terminology is also crucial. This review of the literature intends to summarize and critically discuss the main methodological aspects for accurate design and translational character of preclinical studies.

1 June 2013 in Atherosclerosis
Verified
Journal Article
Closed access
AMA. Millon
A. Millon
SDS.D. Dickson
S.D. Dickson
AKA. Klink
A. Klink
DGDavid Izquierdo Garcia
David Izquierdo Garcia
JBJ. Bini
J. Bini
ZFZ.A. Fayad
Z.A. Fayad